Clinical bottom line
Focal segmental glomerulosclerosis (FSGS) remains a challenging glomerular disease with significant risk of progression to end-stage kidney disease. Emerging therapies targeting podocyte injury, complement activation, and B-cell dysregulation offer promising avenues beyond traditional immunosuppression. Agents such as sparsentan, complement inhibitors, and novel anti-nephrin antibodies are under active investigation, showing potential to reduce proteinuria and preserve renal function. However, clinical experience is limited, and further trials are needed to define optimal patient selection and long-term efficacy (Kohan et al., 2024; Apetrii et al., 2025; Liaukouskaya et al., 2026).
What the evidence shows
Kohan et al. (2024) elucidate the kidney-protective mechanisms of sparsentan, a dual endothelin and angiotensin receptor antagonist, demonstrating significant proteinuria reduction in chronic kidney disease models including FSGS. Sparsentan’s antifibrotic and hemodynamic effects may translate into renal preservation.
Apetrii et al. (2025) review complement system inhibitors as emerging nephrology therapeutics. Given complement activation’s role in podocyte injury and glomerular inflammation, agents targeting C3 and C5 components are being evaluated for FSGS, with early data suggesting potential to attenuate disease progression.
Liaukouskaya et al. (2026) report on the novel anti-nephrin antibody approach, aiming to protect podocyte integrity by modulating nephrin function. This strategy represents a targeted therapy addressing podocytopathies at a molecular level, with preliminary clinical evidence supporting safety and efficacy signals.
Bigatti et al. (2026) discuss B-cell-targeting therapies, including rituximab and newer agents, highlighting their role in modulating immune-mediated podocyte injury in FSGS, particularly in steroid-resistant cases.
Chen et al. (2015) provide a comprehensive overview of molecular genetics in FSGS, underscoring the heterogeneity of pathogenic pathways and the rationale for personalized targeted therapies.
Earlier reviews by Ponticelli et al. (2013) and Thomas et al. (2006) remain relevant for context on traditional immunosuppressive regimens and their limitations, reinforcing the need for novel treatments.
Caveats and uncertainty
Most emerging therapies are supported by early-phase trials or preclinical data; robust randomized controlled trials are pending.
Heterogeneity in FSGS etiology and histologic variants complicates treatment response prediction.
Long-term safety profiles of novel agents, especially complement inhibitors and biologics, require further characterization.
Cost and accessibility may limit widespread adoption.
Biomarkers for patient stratification and treatment monitoring are not yet standardized.
How this may change practice
Clinicians should remain informed about ongoing clinical trials and emerging therapies to identify candidates for novel interventions.
Incorporation of sparsentan and complement inhibitors may complement or replace conventional immunosuppression in select patients.
Molecular diagnostics and genetic testing could guide personalized therapy selection.
Multidisciplinary collaboration involving nephrologists, immunologists, and geneticists will enhance management.
Future guidelines are likely to integrate these emerging options as evidence matures.